ProCE Banner Activity

D2EFT: Second-line DRV- and/or DTG-Containing ART Regimens After First-line NNRTI Failure

Capsule Summary
Conference Coverage
Slideset

In an open-label study, both DTG + DRV/RTV and DTG + (3TC or FTC)/TDF demonstrated noninferior efficacy vs standard of care DRV/RTV + 2 NRTIs.

Released: February 27, 2023

Expiration: February 26, 2024

Begin Activity

Share

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare